



CARG

Cancer & Aging Research Group

CARG MEETING – 1/12/2020

DRS. WILLIAM DALE AND JESSICA KROK-SCHOEN


AGENDA

- **Announcements:** Dr. William Dale (10 mins)
 - National Academies Workshop on Improving the Evidence Base for Older Adults with Cancer Virtual Workshop (January 22, 25, and 27th, 2021)
 - Geriatric Communication Skills Training (February 11-12th, 2021)
 - 2nd Annual Canadian Geriatric Oncology Conference (February 26th, 2021)
 - Clin-STAR Database Questionnaire
 - New Members
- **Geriatric Fitness Assessments in Prospective Study Feedback:** Dr. Victor Orellana-Noia (20 mins)
 - Discussants: Drs. Thuy Koll, Grant Williams, Corinne Leach, Heidi Klepin
- **CARinG Conference Events:** Dr. William Dale (20 mins)

ANNOUNCEMENTS

- **National Academies Workshop on Improving the Evidence Base for Older Adults with Cancer Virtual Workshop (January 22, 25, and 27, 2021)**
- **Geriatric Communication Skills Training (February 11-12th, 2021)**
- **2nd Annual Canadian Geriatric Oncology Conference (February 26th, 2021)**
- **Clin-STAR Database Questionnaire**
- **New Members**
 - *Filipe Coutinho*
 - *Gillian Morrison*
 - *Sei Lee*
 - *Elizabeth Wulff-Burchfield, MD*
 - *Tanyanika Phillips*
 - *Anna Parks*





////

Fitness-directed frontline immunotherapy combinations in older patients with classical Hodgkin lymphoma

Victor M. Orellana-Noia, MD

Winship Cancer Institute | Emory University

01.12.2021






Today's goals:

- BRIEFLY review current treatment of classical Hodgkin lymphoma, focusing on older patients (age >60)
 - Novel agents / treatment regimens
 - Geriatric fitness measures in cHL
- Introduce clinical trial in development
- Discuss incorporation of geriatric fitness measures, including
 - Treatment-determining components
 - Correlative / exploratory measures



Here is where I would appreciate CARG feedback.

Hodgkin lymphoma is different with advancing age





E2496: OS by age

- 20-30% of new HL diagnoses after age 60
- Higher rates of conventional adverse risk markers
- Compared to younger patients:
 - Inferior outcomes with conventional HL regimens
 - Higher rates of toxicity (esp. bleomycin)
- UNDER-REPRESENTED in definitive clinical trials

**NO defined or unified standard of care
in older HL patients**


Older patients still benefit from aggressive therapy



“Conventional” HL regimen: ABVD, AVD, BV-AVD, Stanford V


Only ONE of 254 patients underwent CGA at any point in therapy or follow-up

Targeted therapies in HL – CD30



Dissociation of MMAE:

Cumulative exposure leads to tx-limiting peripheral neuropathy



BV monotherapy in older patients:
 93% ORR, 73% CR – PFS 9.1 months
Rapid responses, often not durable


Brentuximab AVD – concurrent vs sequential

ECHELON-1: A-AVD vs ABVD


- N=186 over age 60: no efficacy difference between A-AVD or ABVD
- Increased hematologic toxicities across all ages with A-AVD

Sequential BV-AVD


- N=48 (all pts over age 60)
- 42% grade 3+ TRAE
- CR 90% after AVDx6; 2-yr PFS: 84%



Targeted therapies in HL – PD1/PDL1




- HRS cells commonly surrounded by ineffective immune infiltration
- Higher HRS PD-L1/PD-L2 expression driven by 9p24.1 genetic amplification





Targeting PD1:
 Similar efficacy with nivolumab, pembrolizumab in R/R setting

iPD1 plus AVD





Low incidence of IRAEs with lead-in ICPI

VERY LOW enrollment in older patients – n=4 (PemAVD), n=6 (NivoAVD)



Phase III trial in progress SWOG 1826: Nivo-AVD vs BV-AVD

Geriatric assessments in classical Hodgkin lymphoma



UK SHIELD study
Age 60+; tx decided by modified ACE-27

High comorbidities assoc. w/ limited tx response and poor OS

Sequential BV-AVD:

- *CIRS-G 10+, impaired IADLs, age >70* → inferior response, shorter survival, greater toxicity

eHL MCR:


- *ADL/IADL impairment* → inferior survival (independent of frontline regimen on MV analysis)
- *CIRS-G 10+, geriatric syndrome, age >70* → greater toxicity



Defining the gaps:

- Chemotherapy remains only known curative systemic approach in cHL
- Necessary duration of chemotherapy unknown in modern cHL regimens
 - Can we use novel agents to de-escalate this?
- Candidacy for chemotherapy often left to MD discretion, without a clear standard
 - Historically poor enrollment in cHL studies beyond age 60
 - “Fitness” not well defined in lymphoma, except through PS and organ function
 - Current lymphoma practice does NOT utilize CGAs – though we do seem to appreciate the importance of comorbidity burden and ADL/IADL status


Phase II trial concept: age 60+, newly dx cHL



*PEM dosing will be **q6 weeks** throughout treatment; duration of lead-in and induction therapy stated in terms of partnered agent(s)



Interim analysis: if no difference between CGA 1 and 2, will move tx determination upfront



CGA

Treatment determining: ADL / IADL, CIRS-G <10 vs 10+

Secondary analysis: 4m walk test, grip strength, MMSE, nutrition (MNA), PRO surveys
[also planned: exploration of fitness, outcomes by MD vs protocol designation]

GOALS with this design:

- 1) Utilize areas we are already collecting well, or are able to incorporate quickly
- 2) Demonstrate utility of more comprehensive testing, prospectively and with modern therapy

CARING VIRTUAL CONFERENCE EVENTS

CARG Zoom Meeting

- **Tuesday, January 26th, 2021**
 - 2:00 PM ET- 3:00 PM ET

Conference Day 1: CARinG Cores Members

- **Thursday, January 28th, 2021**
 - 11:00 AM ET- 4:00 PM ET

Social Event: The Elephant in the Room Meet and Greet Cast

- **Thursday, January 28th, 2021**
 - 8:00 PM ET

Conference Day 2: CARG Members

- **Friday, January 29th, 2021**
 - 11:00 AM ET- 4:00 PM ET



CARG ZOOM MEETING – 1/26/2021

Pre-Conference Event - CARinG Core Introductions


- Analytics Core
- Clinical Implementation Core
- Communications Core
- Health Services Core
- Measures Core
- Supportive Care Core



CONFERENCE DAY 1: CARING CORES MEMBERS

Objectives

- Build excitement and esprit de corps among CARG leadership about progress to date
- Create greater “inter-core” awareness of work going on beyond their own cores
- Provide an opportunity for Cores to convene and discuss future plans, leadership changes, work ahead in the coming year ahead and towards sustainability
- Prepare, as needed, for Day 2 content and presentations



SOCIAL EVENT

The Elephant in the Room

Meet and Greet Cast

Thursday, January 28th, 2021

8:00 pm ET

Zoom Meeting



Funded by NIH/NIA
Grant No. 1R21AG059206

CONFERENCE DAY 2: CARG MEMBERS

Objectives

- Build excitement and esprit de corps among CARG membership about progress to date
- Provide an opportunity for the CARG members to provide input around important issues, notably sustainability
- Generate (virtual) connections among CARG membership

Please complete the survey to register for Conference Day 2.

Everyone is welcome to join!

Registration Link: <https://www.surveymonkey.com/r/CARGConferenceRSVP>

*Please confirm for your attendance by **Friday, January 22nd, 2021***

A zoom meeting link will be sent you a week prior to the event.



CARG
CANCER & AGING RESEARCH GROUP
Infrastructure Grant

Funded by NIH/NIA
Grant No. 1R21AG059206

THANK YOU!

NEXT MEETING: TUESDAY, JANUARY 26, 2021

